Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, has announced that the US Food and Drug Administration (FDA) has approved a change to the prescribing information for its once-daily Attention Deficit Hyperactivity Disorder (ADHD) treatment VYVANSE® (lisdexamfetamine dimesylate) CII, to include supplemental data that demonstrated significant ADHD symptom control Advertisement:
Posted by Vyvanse In the News on at
Filed under Vyvanse News · Tagged with Adhd, Adhd Treatment, Advertisement, Attention Deficit Hyperactivity Disorder, Children With Adhd, Cii, Efficacy, Fda Approved, Food And Drug, Food And Drug Administration, Food And Drug Administration Fda, Hyperactivity, Lse, Nasdaq, Prescribing Information, Shire, Shp, Supplemental Data, Symptom Control, Us Food And Drug Administration
New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) Advertisement:
Posted by Vyvanse In the News on at
Filed under Vyvanse News · Tagged with Adhd, Adhd Medication, Advertisement, Change Profile, Cii, Lisdexamfetamine Dimesylate, Medication, Pharmacokinetic Profile, Ppi, Prilosec, Prilosec Otc, Proton Pump Inhibitor, Vyvanse
